2 results match your criteria: "Keck School of Medicine at University of California Los Angeles[Affiliation]"
Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis.
J Dermatolog Treat
December 2025
Keck School of Medicine at University of California Los Angeles, Los Angeles, CA, USA.
Background: Lebrikizumab monotherapy significantly improved signs and symptoms in patients with moderate-to-severe atopic dermatitis (AD) in phase 3 Advocate1 and ADvocate2 studies.
Objective: To evaluate improvements in patient-reported symptoms and quality-of-life (QoL) measures by Eczema Area and Severity Index (EASI) response categories using pooled Advocate1 and ADvocate2 data (post hoc analysis).
Methods: In the 52-week (W) (16-W induction + 36-W maintenance) double-blind, placebo-controlled ADvocate1 and ADvocate2 studies, patients were randomized (2:1) to receive subcutaneous lebrikizumab 250 mg or placebo every 2 weeks.
Lebrikizumab Improves Quality of Life and Patient-Reported Symptoms of Anxiety and Depression in Patients with Moderate-to-Severe Atopic Dermatitis.
Dermatol Ther (Heidelb)
July 2024
Department of Dermatology, Centro Hospitalar Universitario de Santo António, ICBAS, University of Porto, Porto, Portugal.
Article Synopsis
- Atopic dermatitis (AD) is a long-lasting skin condition that can significantly affect a person's quality of life and mental health.
- A study evaluated the effectiveness of lebrikizumab on quality of life and mental health in patients with moderate-to-severe AD over a 16-week period, using various assessment tools.
- Results showed notable improvements in overall quality of life, anxiety, and depression among those treated with lebrikizumab compared to placebo, indicating its potential benefits for patients suffering from AD.